[HTML][HTML] The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population
TR Wilson, J Yu, X Lu, JM Spoerke, Y Xiao… - NPJ Breast …, 2016 - nature.com
Breast cancer is a heterogeneous disease and patients are managed clinically based on
ER, PR, HER2 expression, and key risk factors. We sought to characterize the molecular …
ER, PR, HER2 expression, and key risk factors. We sought to characterize the molecular …
The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population.
TR Wilson, J Yu, X Lu, JM Spoerke, Y Xiao… - NPJ Breast …, 2016 - europepmc.org
Breast cancer is a heterogeneous disease and patients are managed clinically based on
ER, PR, HER2 expression, and key risk factors. We sought to characterize the molecular …
ER, PR, HER2 expression, and key risk factors. We sought to characterize the molecular …
[PDF][PDF] The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population
TR Wilson, J Yu, X Lu, JM Spoerke, Y Xiao, C O'Brien… - academia.edu
Breast cancer is a heterogeneous disease that is categorized clinically by
immunohistochemical (IHC) staining of the three receptors; estrogen receptor (ER) …
immunohistochemical (IHC) staining of the three receptors; estrogen receptor (ER) …
The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population
TR Wilson, J Yu, X Lu, JM Spoerke, Y Xiao… - NPJ Breast …, 2016 - search.proquest.com
Breast cancer is a heterogeneous disease and patients are managed clinically based on
ER, PR, HER2 expression, and key risk factors. We sought to characterize the molecular …
ER, PR, HER2 expression, and key risk factors. We sought to characterize the molecular …
[PDF][PDF] The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population
TR Wilson, J Yu, X Lu, JM Spoerke, Y Xiao, C O'Brien… - cyberleninka.org
Breast cancer is a heterogeneous disease that is categorized clinically by
immunohistochemical (IHC) staining of the three receptors; estrogen receptor (ER) …
immunohistochemical (IHC) staining of the three receptors; estrogen receptor (ER) …
The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population
TR Wilson, J Yu, X Lu, JM Spoerke… - NPJ breast …, 2016 - pubmed.ncbi.nlm.nih.gov
Breast cancer is a heterogeneous disease and patients are managed clinically based on
ER, PR, HER2 expression, and key risk factors. We sought to characterize the molecular …
ER, PR, HER2 expression, and key risk factors. We sought to characterize the molecular …
[HTML][HTML] The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population
TR Wilson, J Yu, X Lu, JM Spoerke, Y Xiao… - NPJ Breast …, 2016 - ncbi.nlm.nih.gov
Breast cancer is a heterogeneous disease and patients are managed clinically based on
ER, PR, HER2 expression, and key risk factors. We sought to characterize the molecular …
ER, PR, HER2 expression, and key risk factors. We sought to characterize the molecular …
The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population.
TR Wilson, J Yu, X Lu, JM Spoerke, Y Xiao… - NPJ Breast …, 2016 - europepmc.org
Breast cancer is a heterogeneous disease and patients are managed clinically based on
ER, PR, HER2 expression, and key risk factors. We sought to characterize the molecular …
ER, PR, HER2 expression, and key risk factors. We sought to characterize the molecular …